180 related articles for article (PubMed ID: 30714309)
21. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
23. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
24. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract][Full Text] [Related]
25. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
Bajaj HS; Gerstein HC; Rao-Melacini P; Basile J; Colhoun H; Conget I; Cushman WC; Dagenais GR; Franek E; Hanefeld M; Keltai M; Lakshmanan M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Probstfield J; Raubenheimer P; Ryden L; Shaw JE; Sheu WH; Xavier D
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):484-490. PubMed ID: 34153269
[TBL] [Abstract][Full Text] [Related]
26. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
28. Dulaglutide for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
Riddle MC; Gerstein HC; Xavier D; Cushman WC; Leiter LA; Raubenheimer PJ; Atisso CM; Raha S; Varnado OJ; Konig M; Lakshmanan M; Franek E
J Clin Endocrinol Metab; 2021 Apr; 106(5):1345-1351. PubMed ID: 33537745
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
31. SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Shaughnessy AF
Am Fam Physician; 2021 Aug; 104(2):206. PubMed ID: 34383432
[No Abstract] [Full Text] [Related]
32. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
33. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide.
MacIsaac RJ
Future Cardiol; 2021 May; 17(3):459-473. PubMed ID: 33820430
[TBL] [Abstract][Full Text] [Related]
35. Two new GLP-1 receptor agonists for diabetes.
Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
[No Abstract] [Full Text] [Related]
36. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
Ferrannini G; Gerstein H; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Avezum A; Basile JN; Cushman WC; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pais P; Pīrāgs V; Pogosova N; Raubenheimer PJ; Sheu WH; Rydén L
Eur Heart J; 2021 Jul; 42(26):2565-2573. PubMed ID: 33197271
[TBL] [Abstract][Full Text] [Related]
37. Dulaglutide for the treatment of type 2 diabetes.
Amblee A
Drugs Today (Barc); 2014 Apr; 50(4):277-89. PubMed ID: 24918645
[TBL] [Abstract][Full Text] [Related]
38. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
39. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
[TBL] [Abstract][Full Text] [Related]
40. Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
Almeida OP; Fong Z; Hill Almeida LM; Sanfilippo FM; Page A; Etherton-Beer C
Diabetes Obes Metab; 2024 Jul; 26(7):2925-2932. PubMed ID: 38650544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]